Nectar Lifesci.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE023H01027
NSEID: NECLIFE
BSEID: 532649

INR

20.94

0.00 (0.00%)

BSENSE

Dec 05

BSE+NSE Vol: 49.52 lacs

{
  "main_header": {
    "sid": 216478,
    "name": "Nectar Lifesci.",
    "stock_name": "Nectar Lifesci.",
    "full_name": "Nectar Lifescience Ltd",
    "name_url": "stocks-analysis/nectar-lifesci",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "20.94",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "20.94",
    "mcapval": "469.60 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532649,
    "symbol": "NECLIFE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE023H01027",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "49.52 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nectar-lifesci-216478-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Nectar Lifescience Sees Exceptional Trading Volume Amidst Market Activity",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-surges-on-exceptional-volume-amid-strong-sell-rating-3746034",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NectarLifescien_most_active_equities_by_volume_3746034.png",
        "date": "2025-12-04 10:00:12",
        "description": "Nectar Lifescience Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, recorded one of the highest trading volumes on 4 December 2025, with over 1.91 crore shares exchanging hands. The stock demonstrated notable price movement, opening sharply higher and outperforming its sector peers, signalling heightened market interest and active participation despite a decline in delivery volumes."
      },
      {
        "title": "Nectar Lifesci. Sees Revision in Market Evaluation Amidst Challenging Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nectar-lifesci-downgraded-to-strong-sell-amid-deteriorating-fundamentals-3741251",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NectarLifesci_mojoScore_3741251.png",
        "date": "2025-12-02 10:09:20",
        "description": "Nectar Lifesci., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s operational performance, valuation risks, and market behaviour, signalling a cautious stance for investors navigating this volatile stock."
      },
      {
        "title": "Nectar Lifescience Surges with Unprecedented Buying Interest, Hits Upper Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-surges-to-upper-circuit-on-unprecedented-buying-interest-3735716",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NectarLifescien_only_buyers_3735716.png",
        "date": "2025-11-28 13:35:13",
        "description": "Nectar Lifescience Ltd witnessed extraordinary buying momentum on 28 Nov 2025, with the stock hitting the upper circuit limit and registering a near 20% gain in a single trading session. The surge was marked by an absence of sellers, creating a unique scenario where only buy orders were queued, signalling intense demand and potential for a multi-day circuit scenario."
      },
      {
        "title": "Nectar Lifescience Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-surges-176-to-hit-upper-circuit-amid-robust-buying-pressure-3735290",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NectarLifescien_stocks_hitting_upper_circuit_3735290.png",
        "date": "2025-11-28 10:00:14",
        "description": "Nectar Lifescience Ltd witnessed a significant surge in its share price on 28 Nov 2025, hitting the upper circuit limit with a remarkable 17.58% gain. The stock demonstrated robust buying interest, outpacing its sector and broader market indices, while trading volumes and turnover reflected heightened investor participation."
      },
      {
        "title": "Nectar Lifescience Sees Exceptional Trading Volume Amidst Market Activity",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-surges-on-exceptional-volume-amid-strong-market-activity-3735248",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NectarLifescien_most_active_equities_by_volume_3735248.png",
        "date": "2025-11-28 10:00:10",
        "description": "Nectar Lifescience Ltd has emerged as one of the most actively traded stocks on 28 November 2025, registering a significant surge in trading volume and price movement. The pharmaceutical and biotechnology company’s shares witnessed a notable uptick in investor participation, reflecting heightened market interest and dynamic trading patterns."
      },
      {
        "title": "Why is Nectar Lifesci. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-nectar-lifesci-fallingrising-3721940",
        "imagepath": "",
        "date": "2025-11-22 00:41:11",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Short-Term Gains</strong></p>\n<p>The stock has demonstrated a notable recovery in the past month, delivering an 11.19% return compared to the Sensex’s modest 0.95% gain over the same period. This recent momentum is further underscored by the stock’s consecutive gains over the last three trading sessions, during which it has appreciated by 7.64%. On 21-Nov, the share price increased by ₹0.66, outperforming its sector by 5.19%, signalling renewed investor interest and positive sentiment in the near term.</p>\n<p>Technical indicators provide additional context for this rise. The current price stands above the 5-day, 20-day, and 50-day moving averages, suggesting short- to medium-term bullishness. However, it remains below the 100-day and 200-day moving averages, indicat..."
      },
      {
        "title": "Why is Nectar Lifesci. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-nectar-lifesci-fallingrising-3712904",
        "imagepath": "",
        "date": "2025-11-18 22:05:41",
        "description": "As of 18-Nov, Nectar Lifescience Ltd is experiencing a decline in its stock price, currently at Rs 13.75, which represents a decrease of 0.89 or 6.08%. The stock has been underperforming significantly, with a consecutive fall over the last three days resulting in a total drop of 13.63%. It is currently trading lower than all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Additionally, the stock is close to its 52-week low, just 3.64% away from Rs 13.25. The delivery volume has also decreased by 22.67% compared to the 5-day average, indicating falling investor participation. The stock's year-to-date performance shows a staggering decline of 64.74%, contrasting sharply with the Sensex's gain of 8.36%.\n\nIn the broader market context, Nectar Lifescience's short-term performance has been notably poor compared to the benchmark, as it has declined by 5.43% over the past we..."
      },
      {
        "title": "Nectar Lifescience Q2 FY26: Steep Losses Deepen as Operations Collapse",
        "link": "https://www.marketsmojo.com/news/result-analysis/nectar-lifescience-q2-fy26-steep-losses-deepen-as-operations-collapse-3718720",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NectarLifescien_quaterlyResult_3718720.png",
        "date": "2025-11-18 16:20:02",
        "description": "Nectar Lifescience Ltd., a specialised cephalosporins manufacturer, reported a consolidated net loss of ₹176.01 crores for Q2 FY26, marking a catastrophic deterioration from the ₹5.60 crore profit posted in the corresponding quarter last year. The micro-cap pharmaceutical company's operational collapse has accelerated, with revenues plummeting 98.78% quarter-on-quarter to just ₹5.71 crores, signalling severe distress in its core business operations."
      },
      {
        "title": "Nectar Lifescience Faces Financial Challenges Amidst Mixed Operational Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifesciences-financial-trend-improves-from-negative-to-flat-despite-declining-sales-3709568",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NectarLifescien_fintrenddot_3709568.png",
        "date": "2025-11-18 08:00:14",
        "description": "Nectar Lifescience has reported a challenging quarter with a significant decline in financial performance, including a drastic drop in net sales and a negative Profit After Tax. Despite achieving a high Return on Capital Employed and strong receivables management, the company faces increased leverage and struggles to regain market confidence."
      }
    ],
    "total": 552,
    "sid": "216478",
    "stock_news_url": "https://www.marketsmojo.com/news/nectar-lifescience-216478"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "03-Dec-2025",
      "details": "Appointment of Mr. Sushil Kapoor as an additional Director as well Wholetime Director designated as Director (Finance) Executive Director of the company w.e.f. December 04 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Meeting Held On December 03 2025",
      "datetime": "03-Dec-2025",
      "details": "Board of directors of Nectar Lifesciences Limited (Company) in their meeting held on December 03 2025 has considered and approved the following matters: 1. The buyback of equity shares. 2. Other ancillary and general matters.",
      "source": "BSE"
    },
    {
      "caption": "Fixed Record Date For Buyback",
      "datetime": "03-Dec-2025",
      "details": "Record date for the purpose of Buyback is 24-Dec-2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Nectar Lifescience Ltd has declared <strong>5%</strong> dividend, ex-date: 11 Sep 20",
          "dt": "2020-09-11",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Nectar Lifescience Ltd has announced <strong>1:10</strong> stock split, ex-date: 12 Nov 08",
          "dt": "2008-11-12",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Nectar Lifescience Sees Exceptional Trading Volume Amidst Market Activity

2025-12-04 10:00:12

Nectar Lifescience Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, recorded one of the highest trading volumes on 4 December 2025, with over 1.91 crore shares exchanging hands. The stock demonstrated notable price movement, opening sharply higher and outperforming its sector peers, signalling heightened market interest and active participation despite a decline in delivery volumes.

Nectar Lifesci. Sees Revision in Market Evaluation Amidst Challenging Financials

2025-12-02 10:09:20

Nectar Lifesci., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s operational performance, valuation risks, and market behaviour, signalling a cautious stance for investors navigating this volatile stock.

Nectar Lifescience Surges with Unprecedented Buying Interest, Hits Upper Circuit

2025-11-28 13:35:13

Nectar Lifescience Ltd witnessed extraordinary buying momentum on 28 Nov 2025, with the stock hitting the upper circuit limit and registering a near 20% gain in a single trading session. The surge was marked by an absence of sellers, creating a unique scenario where only buy orders were queued, signalling intense demand and potential for a multi-day circuit scenario.

Nectar Lifescience Hits Upper Circuit Amid Strong Buying Pressure

2025-11-28 10:00:14

Nectar Lifescience Ltd witnessed a significant surge in its share price on 28 Nov 2025, hitting the upper circuit limit with a remarkable 17.58% gain. The stock demonstrated robust buying interest, outpacing its sector and broader market indices, while trading volumes and turnover reflected heightened investor participation.

Nectar Lifescience Sees Exceptional Trading Volume Amidst Market Activity

2025-11-28 10:00:10

Nectar Lifescience Ltd has emerged as one of the most actively traded stocks on 28 November 2025, registering a significant surge in trading volume and price movement. The pharmaceutical and biotechnology company’s shares witnessed a notable uptick in investor participation, reflecting heightened market interest and dynamic trading patterns.

Why is Nectar Lifesci. falling/rising?

2025-11-22 00:41:11

Recent Price Movement and Short-Term Gains

The stock has demonstrated a notable recovery in the past month, delivering an 11.19% return compared to the Sensex’s modest 0.95% gain over the same period. This recent momentum is further underscored by the stock’s consecutive gains over the last three trading sessions, during which it has appreciated by 7.64%. On 21-Nov, the share price increased by ₹0.66, outperforming its sector by 5.19%, signalling renewed investor interest and positive sentiment in the near term.

Technical indicators provide additional context for this rise. The current price stands above the 5-day, 20-day, and 50-day moving averages, suggesting short- to medium-term bullishness. However, it remains below the 100-day and 200-day moving averages, indicat...

Why is Nectar Lifesci. falling/rising?

2025-11-18 22:05:41

As of 18-Nov, Nectar Lifescience Ltd is experiencing a decline in its stock price, currently at Rs 13.75, which represents a decrease of 0.89 or 6.08%. The stock has been underperforming significantly, with a consecutive fall over the last three days resulting in a total drop of 13.63%. It is currently trading lower than all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Additionally, the stock is close to its 52-week low, just 3.64% away from Rs 13.25. The delivery volume has also decreased by 22.67% compared to the 5-day average, indicating falling investor participation. The stock's year-to-date performance shows a staggering decline of 64.74%, contrasting sharply with the Sensex's gain of 8.36%. In the broader market context, Nectar Lifescience's short-term performance has been notably poor compared to the benchmark, as it has declined by 5.43% over the past we...

Nectar Lifescience Q2 FY26: Steep Losses Deepen as Operations Collapse

2025-11-18 16:20:02

Nectar Lifescience Ltd., a specialised cephalosporins manufacturer, reported a consolidated net loss of ₹176.01 crores for Q2 FY26, marking a catastrophic deterioration from the ₹5.60 crore profit posted in the corresponding quarter last year. The micro-cap pharmaceutical company's operational collapse has accelerated, with revenues plummeting 98.78% quarter-on-quarter to just ₹5.71 crores, signalling severe distress in its core business operations.

Nectar Lifescience Faces Financial Challenges Amidst Mixed Operational Performance Metrics

2025-11-18 08:00:14

Nectar Lifescience has reported a challenging quarter with a significant decline in financial performance, including a drastic drop in net sales and a negative Profit After Tax. Despite achieving a high Return on Capital Employed and strong receivables management, the company faces increased leverage and struggles to regain market confidence.

View All News

Announcement

Announcement under Regulation 30 (LODR)-Change in Management

03-Dec-2025 | Source : BSE

Appointment of Mr. Sushil Kapoor as an additional Director as well Wholetime Director designated as Director (Finance) Executive Director of the company w.e.f. December 04 2025.

Board Meeting Outcome for Meeting Held On December 03 2025

03-Dec-2025 | Source : BSE

Board of directors of Nectar Lifesciences Limited (Company) in their meeting held on December 03 2025 has considered and approved the following matters: 1. The buyback of equity shares. 2. Other ancillary and general matters.